<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en-GB">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>MBNMAdose: Package Overview • MBNMAdose</title>
<!-- jquery --><script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.7.1/jquery.min.js" integrity="sha512-v2CJ7UaYy4JwqLDIrZUI/4hqeoQieOmAZNXBeQyjo21dadnwR+8ZaIJVT8EE2iyI61OV8e6M8PP2/4hpQINQ/g==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><!-- Bootstrap --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/css/bootstrap.min.css" integrity="sha256-bZLfwXAP04zRMK2BjiO8iu9pf4FbLqX6zitd+tIvLhE=" crossorigin="anonymous">
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.4.1/js/bootstrap.min.js" integrity="sha256-nuL8/2cJ5NDSSwnKD8VqreErSWHtnEP9E7AySL+1ev4=" crossorigin="anonymous"></script><!-- bootstrap-toc --><link rel="stylesheet" href="../bootstrap-toc.css">
<script src="../bootstrap-toc.js"></script><!-- Font Awesome icons --><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/all.min.css" integrity="sha256-mmgLkCYLUQbXn0B1SRqzHar6dCnv9oZFPEC1g1cwlkk=" crossorigin="anonymous">
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.12.1/css/v4-shims.min.css" integrity="sha256-wZjR52fzng1pJHwx4aV2AO3yyTOXrcDW7jBpJtTwVxw=" crossorigin="anonymous">
<!-- clipboard.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><!-- headroom.js --><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/headroom.min.js" integrity="sha256-AsUX4SJE1+yuDu5+mAVzJbuYNPHj/WroHuZ8Ir/CkE0=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/headroom/0.11.0/jQuery.headroom.min.js" integrity="sha256-ZX/yNShbjqsohH1k95liqY9Gd8uOiE1S4vZc+9KQ1K4=" crossorigin="anonymous"></script><!-- pkgdown --><link href="../pkgdown.css" rel="stylesheet">
<script src="../pkgdown.js"></script><meta property="og:title" content="MBNMAdose: Package Overview">
<!-- mathjax --><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/MathJax.js" integrity="sha256-nvJJv9wWKEm88qvoQl9ekL2J+k/RWIsaSScxxlsrv8k=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.5/config/TeX-AMS-MML_HTMLorMML.js" integrity="sha256-84DKXVJXs0/F8OTMzX4UR909+jtl4G7SPypPavF+GfA=" crossorigin="anonymous"></script><!--[if lt IE 9]>
<script src="https://oss.maxcdn.com/html5shiv/3.7.3/html5shiv.min.js"></script>
<script src="https://oss.maxcdn.com/respond/1.4.2/respond.min.js"></script>
<![endif]-->
</head>
<body data-spy="scroll" data-target="#toc">


    <div class="container template-article">
      <header><div class="navbar navbar-default navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <span class="navbar-brand">
        <a class="navbar-link" href="../index.html">MBNMAdose</a>
        <span class="version label label-default" data-toggle="tooltip" data-placement="bottom" title="">0.5.0</span>
      </span>
    </div>

    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
<li>
  <a href="../reference/index.html">Reference</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    Articles

    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
<li>
      <a href="../articles/consistencychecking-3.html">MBNMAdose: Checking for consistency</a>
    </li>
    <li>
      <a href="../articles/dataexploration-1.html">MBNMAdose: Exploring the data</a>
    </li>
    <li>
      <a href="../articles/mbnmadose-overview.html">MBNMAdose: Package Overview</a>
    </li>
    <li>
      <a href="../articles/metaregression-6.html">MBNMAdose: Perform Network Meta-Regression</a>
    </li>
    <li>
      <a href="../articles/nma_in_mbnmadose.html">Class effect NMA analysis using MBNMAdose</a>
    </li>
    <li>
      <a href="../articles/outputs-4.html">MBNMAdose outputs: Relative effects, forest plots and rankings</a>
    </li>
    <li>
      <a href="../articles/predictions-5.html">MBNMAdose: Calculating model predictions</a>
    </li>
    <li>
      <a href="../articles/runmbnmadose-2.html">MBNMAdose: Perform a Model-Based Network Meta-Analysis (MBNMA)</a>
    </li>
  </ul>
</li>
<li>
  <a href="../news/index.html">Changelog</a>
</li>
      </ul>
<ul class="nav navbar-nav navbar-right"></ul>
</div>
<!--/.nav-collapse -->
  </div>
<!--/.container -->
</div>
<!--/.navbar -->



      </header><div class="row">
  <div class="col-md-9 contents">
    <div class="page-header toc-ignore">
      <h1 data-toc-skip>MBNMAdose: Package Overview</h1>
                        <h4 data-toc-skip class="author">Hugo
Pedder</h4>
            
            <h4 data-toc-skip class="date">2025-05-20</h4>
      

      <div class="hidden name"><code>mbnmadose-overview.Rmd</code></div>

    </div>

    
    
<div class="section level2">
<h2 id="introduction">Introduction<a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>This vignette demonstrates how to use <code>MBNMAdose</code> to
perform Model-Based Network Meta-Analysis (MBNMA) of studies with
multiple doses of different agents by accounting for the dose-response
relationship. This can connect disconnected networks via the
dose-response relationship and the placebo response, improve precision
of estimated effects and allow interpolation/extrapolation of predicted
response based on the dose-response relationship.</p>
<p>Modelling the dose-response relationship also avoids the “lumping” of
different doses of an agent which is often done in Network Meta-Analysis
(NMA) and can introduce additional heterogeneity or inconsistency. All
models and analyses are implemented in a Bayesian framework, following
an extension of the standard NMA methodology presented by <span class="citation">(Lu and Ades 2004)</span> and are run in JAGS
<em>(version 4.3.0 or later is required)</em> <span class="citation">(2017)</span>. For full details of dose-response MBNMA
methodology see Mawdsley et al. <span class="citation">(2016)</span>.
Throughout this vignette we refer to a <strong>treatment</strong> as a
specific <strong>dose</strong> or a specific <strong>agent</strong></p>
<p>This package has been developed alongside <code>MBNMAtime</code>, a
package that allows users to perform time-course MBNMA to incorporate
multiple time points within different studies. However, <em>they should
not be loaded into R at the same time</em> as there are a number of
functions with shared names that perform similar tasks yet are specific
to dealing with either time-course <em>or</em> dose-response data.</p>
<div class="section level3">
<h3 id="workflow-within-the-package">Workflow within the package<a class="anchor" aria-label="anchor" href="#workflow-within-the-package"></a>
</h3>
<p>Functions within <code>MBNMAdose</code> follow a clear pattern of
use:</p>
<ol style="list-style-type: decimal">
<li>Load your data into the correct format using
<code><a href="../reference/mbnma.network.html">mbnma.network()</a></code> and explore potential relationships (<a href="dataexploration-1.html">Exploring the data</a>
</li>
<li>Perform a dose-response MBNMA using <code><a href="../reference/mbnma.run.html">mbnma.run()</a></code> (<a href="runmbnmadose-2.html">Performing a dose-response MBNMA</a>.
Modelling of effect modifying covariates is also possibly using <a href="metaregression-6.html">Network Meta-Regression</a>.</li>
<li>Test for consistency at the treatment-level using functions like
<code><a href="../reference/nma.nodesplit.html">nma.nodesplit()</a></code> and <code><a href="../reference/nma.run.html">nma.run()</a></code> (<a href="consistencychecking-3.html">Checking for consistency</a>
</li>
<li>Examine model outputs, such as relative effects, forest plots and
treatment rankings (<a href="outputs-4.html">Model outputs</a>
</li>
<li>Use your model to predict responses using <code><a href="https://rdrr.io/r/stats/predict.html" class="external-link">predict()</a></code> (<a href="predictions-5.html">Predictions</a>
</li>
</ol>
<p>At each of these stages there are a number of informative plots that
can be generated to help understand the data and to make decisions
regarding model fitting.</p>
</div>
</div>
<div class="section level2">
<h2 id="datasets-included-in-the-package">Datasets Included in the Package<a class="anchor" aria-label="anchor" href="#datasets-included-in-the-package"></a>
</h2>
<div class="section level3">
<h3 id="triptans-for-migraine-pain-relief">Triptans for migraine pain relief<a class="anchor" aria-label="anchor" href="#triptans-for-migraine-pain-relief"></a>
</h3>
<p><code>triptans</code> is from a systematic review of interventions
for pain relief in migraine <span class="citation">(Thorlund et al.
2014)</span>. The outcome is binary, and represents (as aggregate data)
the number of participants who were headache-free at 2 hours. Data are
from patients who had had at least one migraine attack, who were not
lost to follow-up, and who did not violate the trial protocol. The
dataset includes 70 Randomised-Controlled Trials (RCTs), comparing 7
triptans with placebo. Doses are standardised as relative to a “common”
dose, and in total there are 23 different treatments (combination of
dose and agent). <code>triptans</code> is a data frame in long format
(one row per arm and study), with the variables <code>studyID</code>,
<code>AuthorYear</code>, <code>N</code>, <code>r</code>,
<code>dose</code> and <code>agent</code>.</p>
<table class="table">
<thead><tr class="header">
<th align="right">studyID</th>
<th align="left">AuthorYear</th>
<th align="right">n</th>
<th align="right">r</th>
<th align="right">dose</th>
<th align="left">agent</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="right">1</td>
<td align="left">Tfelt-Hansen P 2006</td>
<td align="right">22</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="left">placebo</td>
</tr>
<tr class="even">
<td align="right">1</td>
<td align="left">Tfelt-Hansen P 2006</td>
<td align="right">30</td>
<td align="right">14</td>
<td align="right">1</td>
<td align="left">sumatriptan</td>
</tr>
<tr class="odd">
<td align="right">2</td>
<td align="left">Goadsby PJ 2007</td>
<td align="right">467</td>
<td align="right">213</td>
<td align="right">1</td>
<td align="left">almotriptan</td>
</tr>
<tr class="even">
<td align="right">2</td>
<td align="left">Goadsby PJ 2007</td>
<td align="right">472</td>
<td align="right">229</td>
<td align="right">1</td>
<td align="left">zolmitriptan</td>
</tr>
<tr class="odd">
<td align="right">3</td>
<td align="left">Tuchman M2006</td>
<td align="right">160</td>
<td align="right">15</td>
<td align="right">0</td>
<td align="left">placebo</td>
</tr>
<tr class="even">
<td align="right">3</td>
<td align="left">Tuchman M2006</td>
<td align="right">174</td>
<td align="right">48</td>
<td align="right">1</td>
<td align="left">zolmitriptan</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="biologics-for-treatment-of-moderate-to-severe-psoriasis">Biologics for treatment of moderate-to-severe psoriasis<a class="anchor" aria-label="anchor" href="#biologics-for-treatment-of-moderate-to-severe-psoriasis"></a>
</h3>
<p>There are 3 psoriasis datasets from a systematic review of RCTs
comparing biologics at different doses and placebo <span class="citation">(Warren et al. 2019)</span>. Each dataset contains a
different binary outcome, all based on the number of patients
experiencing degrees of improvement on the Psoriasis Area and Severity
Index (PASI) measured at 12 weeks follow-up. Each dataset contains
information on the number of participants who achieved
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>75</mn><mi>%</mi></mrow><annotation encoding="application/x-tex">\geq75\%</annotation></semantics></math>
(<code>psoriasis75</code>),
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mo>≥</mo><mn>90</mn><mi>%</mi></mrow><annotation encoding="application/x-tex">\geq90\%</annotation></semantics></math>
(<code>psoriasis90</code>), or
<math display="inline" xmlns="http://www.w3.org/1998/Math/MathML"><semantics><mrow><mn>100</mn><mi>%</mi></mrow><annotation encoding="application/x-tex">100\%</annotation></semantics></math>
(<code>psoriasis100</code>).</p>
</div>
<div class="section level3">
<h3 id="selective-serotonin-reuptake-inhibitors-ssris-for-major-depression">Selective Serotonin Reuptake Inhibitors (SSRIs) for major
depression<a class="anchor" aria-label="anchor" href="#selective-serotonin-reuptake-inhibitors-ssris-for-major-depression"></a>
</h3>
<p><code>ssri</code> is from a systematic review examining the efficacy
of different doses of SSRI antidepressant drugs and placebo <span class="citation">(Furukawa et al. 2019)</span>. The response to
treatment is defined as a 50% reduction in depressive symptoms after 8
weeks (4-12 week range) follow-up. The dataset includes 60 RCTs
comparing 5 different SSRIs with placebo.</p>
<div class="sourceCode" id="cb1"><pre class="downlit sourceCode r">
<code class="sourceCode R"><span><span class="fu">kable</span><span class="op">(</span><span class="fu"><a href="https://rdrr.io/r/utils/head.html" class="external-link">head</a></span><span class="op">(</span><span class="va">ssri</span><span class="op">)</span>, digits <span class="op">=</span> <span class="fl">2</span><span class="op">)</span></span></code></pre></div>
<table class="table">
<thead><tr class="header">
<th align="right">studyID</th>
<th align="left">bias</th>
<th align="right">age</th>
<th align="right">weeks</th>
<th align="left">agent</th>
<th align="right">dose</th>
<th align="right">n</th>
<th align="right">r</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="right">1</td>
<td align="left">Moderate risk</td>
<td align="right">43.0</td>
<td align="right">6</td>
<td align="left">placebo</td>
<td align="right">0</td>
<td align="right">149</td>
<td align="right">69</td>
</tr>
<tr class="even">
<td align="right">1</td>
<td align="left">Moderate risk</td>
<td align="right">42.9</td>
<td align="right">6</td>
<td align="left">fluoxetine</td>
<td align="right">20</td>
<td align="right">137</td>
<td align="right">77</td>
</tr>
<tr class="odd">
<td align="right">2</td>
<td align="left">Low risk</td>
<td align="right">41.2</td>
<td align="right">6</td>
<td align="left">placebo</td>
<td align="right">0</td>
<td align="right">137</td>
<td align="right">63</td>
</tr>
<tr class="even">
<td align="right">2</td>
<td align="left">Low risk</td>
<td align="right">40.9</td>
<td align="right">6</td>
<td align="left">paroxetine</td>
<td align="right">20</td>
<td align="right">138</td>
<td align="right">74</td>
</tr>
<tr class="odd">
<td align="right">7</td>
<td align="left">Low risk</td>
<td align="right">41.6</td>
<td align="right">6</td>
<td align="left">placebo</td>
<td align="right">0</td>
<td align="right">158</td>
<td align="right">91</td>
</tr>
<tr class="even">
<td align="right">7</td>
<td align="left">Low risk</td>
<td align="right">41.3</td>
<td align="right">6</td>
<td align="left">fluoxetine</td>
<td align="right">20</td>
<td align="right">148</td>
<td align="right">89</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="interventions-for-serum-uric-acid-sua-reduction-in-gout">Interventions for Serum Uric Acid (SUA) reduction in gout<a class="anchor" aria-label="anchor" href="#interventions-for-serum-uric-acid-sua-reduction-in-gout"></a>
</h3>
<p><code>gout</code> is from a systematic review of interventions for
lowering Serum Uric Acid (SUA) concentration in patients with gout
<em>[not published previously]</em>. The outcome is continuous, and
aggregate data responses correspond to the mean change from baseline in
SUA in mg/dL at 2 weeks follow-up. The dataset includes 10
Randomised-Controlled Trials (RCTs), comparing 5 different agents, and
placebo. Data for one agent (RDEA) arises from an RCT that is not
placebo-controlled, and so is not connected to the network directly. In
total there were 19 different treatments (combination of dose and
agent). <code>gout</code> is a data frame in long format (one row per
arm and study), with the variables <code>studyID</code>, <code>y</code>,
<code>se</code>, <code>agent</code> and <code>dose</code>.</p>
<table class="table">
<thead><tr class="header">
<th align="left"></th>
<th align="right">studyID</th>
<th align="right">y</th>
<th align="right">se</th>
<th align="left">agent</th>
<th align="right">dose</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">4</td>
<td align="right">1102</td>
<td align="right">-0.53</td>
<td align="right">0.25</td>
<td align="left">RDEA</td>
<td align="right">100</td>
</tr>
<tr class="even">
<td align="left">5</td>
<td align="right">1102</td>
<td align="right">-1.37</td>
<td align="right">0.18</td>
<td align="left">RDEA</td>
<td align="right">200</td>
</tr>
<tr class="odd">
<td align="left">6</td>
<td align="right">1102</td>
<td align="right">-1.73</td>
<td align="right">0.25</td>
<td align="left">RDEA</td>
<td align="right">400</td>
</tr>
<tr class="even">
<td align="left">53</td>
<td align="right">2001</td>
<td align="right">-6.82</td>
<td align="right">0.06</td>
<td align="left">Febu</td>
<td align="right">240</td>
</tr>
<tr class="odd">
<td align="left">54</td>
<td align="right">2001</td>
<td align="right">0.15</td>
<td align="right">0.04</td>
<td align="left">Plac</td>
<td align="right">0</td>
</tr>
<tr class="even">
<td align="left">92</td>
<td align="right">2003</td>
<td align="right">-3.43</td>
<td align="right">0.03</td>
<td align="left">Allo</td>
<td align="right">300</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="interventions-for-pain-relief-in-osteoarthritis">Interventions for pain relief in osteoarthritis<a class="anchor" aria-label="anchor" href="#interventions-for-pain-relief-in-osteoarthritis"></a>
</h3>
<p><code>osteopain</code> is from a systematic review of interventions
for pain relief in osteoarthritis, used previously in Pedder et al.
<span class="citation">(2019)</span>. The outcome is continuous, and
aggregate data responses correspond to the mean WOMAC pain score at 2
weeks follow-up. The dataset includes 18 Randomised-Controlled Trials
(RCTs), comparing 8 different agents with placebo. In total there were
26 different treatments (combination of dose and agent). The active
treatments can also be grouped into 3 different classes, within which
they have similar mechanisms of action. <code>osteopain_2wkabs</code> is
a data frame in long format (one row per arm and study), with the
variables <code>studyID</code>, <code>agent</code>, <code>dose</code>,
<code>class</code>, <code>y</code>, <code>se</code>, and
<code>N</code>.</p>
<table class="table">
<thead><tr class="header">
<th align="left"></th>
<th align="right">studyID</th>
<th align="left">agent</th>
<th align="right">dose</th>
<th align="left">class</th>
<th align="right">y</th>
<th align="right">se</th>
<th align="right">n</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">13</td>
<td align="right">1</td>
<td align="left">Placebo</td>
<td align="right">0</td>
<td align="left">Placebo</td>
<td align="right">6.26</td>
<td align="right">0.23</td>
<td align="right">60</td>
</tr>
<tr class="even">
<td align="left">14</td>
<td align="right">1</td>
<td align="left">Etoricoxib</td>
<td align="right">10</td>
<td align="left">Cox2Inhib</td>
<td align="right">5.08</td>
<td align="right">0.16</td>
<td align="right">114</td>
</tr>
<tr class="odd">
<td align="left">15</td>
<td align="right">1</td>
<td align="left">Etoricoxib</td>
<td align="right">30</td>
<td align="left">Cox2Inhib</td>
<td align="right">4.42</td>
<td align="right">0.17</td>
<td align="right">102</td>
</tr>
<tr class="even">
<td align="left">16</td>
<td align="right">1</td>
<td align="left">Etoricoxib</td>
<td align="right">5</td>
<td align="left">Cox2Inhib</td>
<td align="right">5.34</td>
<td align="right">0.16</td>
<td align="right">117</td>
</tr>
<tr class="odd">
<td align="left">17</td>
<td align="right">1</td>
<td align="left">Etoricoxib</td>
<td align="right">60</td>
<td align="left">Cox2Inhib</td>
<td align="right">3.62</td>
<td align="right">0.17</td>
<td align="right">112</td>
</tr>
<tr class="even">
<td align="left">18</td>
<td align="right">1</td>
<td align="left">Etoricoxib</td>
<td align="right">90</td>
<td align="left">Cox2Inhib</td>
<td align="right">4.08</td>
<td align="right">0.17</td>
<td align="right">112</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="alogliptin-for-lowering-blood-glucose-concentration-in-type-ii-diabetes">Alogliptin for lowering blood glucose concentration in type II
diabetes<a class="anchor" aria-label="anchor" href="#alogliptin-for-lowering-blood-glucose-concentration-in-type-ii-diabetes"></a>
</h3>
<p><code>alog_pcfb</code> is from a systematic review of
Randomised-Controlled Trials (RCTs) comparing different doses of
alogliptin with placebo <span class="citation">(Langford et al.
2016)</span>. The systematic review was simply performed and was
intended to provide data to illustrate a statistical methodology rather
than for clinical inference. Alogliptin is a treatment aimed at reducing
blood glucose concentration in type II diabetes. The outcome is
continuous, and aggregate data responses correspond to the mean change
in HbA1c from baseline to follow-up in studies of at least 12 weeks
follow-up. The dataset includes 14 RCTs, comparing 5 different doses of
alogliptin with placebo, leading to 6 different treatments (combination
of dose and agent) within the network. <code>alog_pcfb</code> is a data
frame in long format (one row per arm and study), with the variables
<code>studyID</code>, <code>agent</code>, <code>dose</code>,
<code>y</code>, <code>se</code>, and <code>N</code>.</p>
<table class="table">
<thead><tr class="header">
<th align="left">studyID</th>
<th align="left">agent</th>
<th align="right">dose</th>
<th align="right">y</th>
<th align="right">se</th>
<th align="right">n</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">NCT01263470</td>
<td align="left">alogliptin</td>
<td align="right">0.00</td>
<td align="right">0.06</td>
<td align="right">0.05</td>
<td align="right">75</td>
</tr>
<tr class="even">
<td align="left">NCT01263470</td>
<td align="left">alogliptin</td>
<td align="right">6.25</td>
<td align="right">-0.51</td>
<td align="right">0.08</td>
<td align="right">79</td>
</tr>
<tr class="odd">
<td align="left">NCT01263470</td>
<td align="left">alogliptin</td>
<td align="right">12.50</td>
<td align="right">-0.70</td>
<td align="right">0.06</td>
<td align="right">84</td>
</tr>
<tr class="even">
<td align="left">NCT01263470</td>
<td align="left">alogliptin</td>
<td align="right">25.00</td>
<td align="right">-0.76</td>
<td align="right">0.06</td>
<td align="right">79</td>
</tr>
<tr class="odd">
<td align="left">NCT01263470</td>
<td align="left">alogliptin</td>
<td align="right">50.00</td>
<td align="right">-0.82</td>
<td align="right">0.05</td>
<td align="right">79</td>
</tr>
<tr class="even">
<td align="left">NCT00286455</td>
<td align="left">alogliptin</td>
<td align="right">0.00</td>
<td align="right">-0.13</td>
<td align="right">0.08</td>
<td align="right">63</td>
</tr>
</tbody>
</table>
</div>
<div class="section level3">
<h3 id="wound-closure-methods-for-reducing-surgical-site-infection-ssi">Wound closure methods for reducing Surgical Site Infection
(SSI)<a class="anchor" aria-label="anchor" href="#wound-closure-methods-for-reducing-surgical-site-infection-ssi"></a>
</h3>
<p><code>ssi_closure</code> is from a systematic review examining the
efficacy of different wound closure methods to reduce Surgical Site
Infections (SSI). The outcome is binary and represents the number of
patients who experienced a SSI. The dataset includes 129 RCTs comparing
16 different interventions in 6 classes. This dataset is primarily used
to illustrate how <code>MBNMAdose</code> can be used to perform
different types of network meta-analysis without dose-response
information. It is in long format (one row per study arm) and includes
the variables <code>studyID</code>, <code>Year</code>, <code>n</code>,
<code>r</code>, <code>trt</code> and <code>class</code>.</p>
<table class="table">
<thead><tr class="header">
<th align="left">studyID</th>
<th align="right">Year</th>
<th align="right">r</th>
<th align="right">n</th>
<th align="left">trt</th>
<th align="left">class</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Chughtai2000_51</td>
<td align="right">2000</td>
<td align="right">9</td>
<td align="right">81</td>
<td align="left">Suture-absorbable</td>
<td align="left">Suture</td>
</tr>
<tr class="even">
<td align="left">Chughtai2000_51</td>
<td align="right">2000</td>
<td align="right">9</td>
<td align="right">81</td>
<td align="left">Clips</td>
<td align="left">Clips</td>
</tr>
<tr class="odd">
<td align="left">Johnson1997_52</td>
<td align="right">1997</td>
<td align="right">24</td>
<td align="right">258</td>
<td align="left">Suture–monofilament</td>
<td align="left">Suture</td>
</tr>
<tr class="even">
<td align="left">Johnson1997_52</td>
<td align="right">1997</td>
<td align="right">23</td>
<td align="right">258</td>
<td align="left">Staples</td>
<td align="left">Staples</td>
</tr>
<tr class="odd">
<td align="left">Mullen1999_53</td>
<td align="right">1999</td>
<td align="right">3</td>
<td align="right">40</td>
<td align="left">Suture</td>
<td align="left">Suture</td>
</tr>
<tr class="even">
<td align="left">Mullen1999_53</td>
<td align="right">1999</td>
<td align="right">6</td>
<td align="right">40</td>
<td align="left">Staples</td>
<td align="left">Staples</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level2 unnumbered">
<h2 class="unnumbered" id="references">References<a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<div id="refs" class="references csl-bib-body hanging-indent" entry-spacing="0">
<div id="ref-furukawa2019" class="csl-entry">
Furukawa, T. A., A. Cipriani, P. J. Cowen, S. Leucht, M. Egger, and G.
Salanti. 2019. <span>“Optimal Dose of Selective Serotonin Reuptake
Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A
Systematic Review and Dose-Response Meta-Analysis.”</span> Journal
Article. <em>Lancet Psychiatry</em> 6: 601–9.
</div>
<div id="ref-jags" class="csl-entry">
JAGS Computer Program. 2017. <a href="https://mcmc-jags.sourceforge.io/" class="external-link">https://mcmc-jags.sourceforge.io/</a>.
</div>
<div id="ref-langford2016" class="csl-entry">
Langford, O., J. K. Aronson, G. van Valkenhoef, and R. J. Stevens. 2016.
<span>“Methods for Meta-Analysis of Pharmacodynamic Dose-Response Data
with Application to Multi-Arm Studies of Alogliptin.”</span> Journal
Article. <em>Stat Methods Med Res</em>. <a href="https://doi.org/10.1177/0962280216637093" class="external-link">https://doi.org/10.1177/0962280216637093</a>.
</div>
<div id="ref-lu2004" class="csl-entry">
Lu, G., and A. E. Ades. 2004. <span>“Combination of Direct and Indirect
Evidence in Mixed Treatment Comparisons.”</span> Journal Article.
<em>Stat Med</em> 23 (20): 3105–24. <a href="https://doi.org/10.1002/sim.1875" class="external-link">https://doi.org/10.1002/sim.1875</a>.
</div>
<div id="ref-mawdsley2016" class="csl-entry">
Mawdsley, D., M. Bennetts, S. Dias, M. Boucher, and N. J. Welton. 2016.
<span>“Model-Based Network Meta-Analysis: A Framework for Evidence
Synthesis of Clinical Trial Data.”</span> Journal Article. <em>CPT
Pharmacometrics Syst Pharmacol</em> 5 (8): 393–401. <a href="https://doi.org/10.1002/psp4.12091" class="external-link">https://doi.org/10.1002/psp4.12091</a>.
</div>
<div id="ref-pedder2019" class="csl-entry">
Pedder, H., S. Dias, M. Bennetts, M. Boucher, and N. J. Welton. 2019.
<span>“Modelling Time-Course Relationships with Multiple Treatments:
Model-Based Network Meta-Analysis for Continuous Summary
Outcomes.”</span> Journal Article. <em>Res Synth Methods</em> 10 (2):
267–86.
</div>
<div id="ref-thorlund2014" class="csl-entry">
Thorlund, K., E. J. Mills, P. Wu, E. P. Ramos, A. Chatterjee, E. Druyts,
and P. J. Godsby. 2014. <span>“Comparative Efficacy of Triptans for the
Abortive Treatment of Migraine: A Multiple Treatment Comparison
Meta-Analysis.”</span> Journal Article. <em>Cephalagia</em>. <a href="https://doi.org/10.1177/0333102413508661" class="external-link">https://doi.org/10.1177/0333102413508661</a>.
</div>
<div id="ref-warren2019" class="csl-entry">
Warren, R. B., M. Gooderham, R. Burge, B. Zhu, D. Amato, K. H. Liu, D.
Shrom, J. Guo, A. Brnabic, and A. Blauvelt. 2019. <span>“Comparison of
Cumulative Clinical Benefits of Biologics for the Treatment of Psoriasis
over 16 Weeks: Results from a Network Meta-Analysis.”</span> Journal
Article. <em>J Am Acad Dermatol</em> 82 (5): 1138–49.
</div>
</div>
</div>
  </div>

  <div class="col-md-3 hidden-xs hidden-sm" id="pkgdown-sidebar">

      </div>

</div>



      <footer><div class="copyright">
  <p></p>
<p>Developed by Hugo Pedder.</p>
</div>

<div class="pkgdown">
  <p></p>
<p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.2.</p>
</div>

      </footer>
</div>






  </body>
</html>
